- Details
- Bone strengthening agents such as bisphosphonates or the RANKL-targeting antibody denosumab reduced the bone loss associated with androgen deprivation therapy (ADT) and prevent skeletal-related events in castration resistant prostate cancer (CRPC). The use of these agents is recommended in CRPC by many guidelines. The randomized phase III EORTC-1333-GUCG also known as the PEACE-III trial, compares...
|
- Details
- Real-world data on the use, survival impacts and efficacy of life-prolonging therapies for metastatic castration-resistant prostate cancer (mCRPC) are limited. In this conversation with Alicia Morgans, MD, MPH, Celestia Higano, MD highlights the publication Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in...
|
- Details
- Benjamin Maughan, MD joins Charles Ryan, MD in a discussion on investigational therapy currently being testing of a combination of enzalutamide and radium-223 compared to enzalutamide alone, both FDA-approved therapies for metastatic castration-resistant prostate cancer (mCRPC). This was a randomized study, patients were randomized to standard of care and enzalutamide or six cycles of radium plus...
|
- Details
- Joining Alicia Morgans to discuss a plenary abstract presentation from the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) is Atish D. Choudhury, MD, Ph.D. Dr. Choudhury and colleagues presented the results of a phase II study to assess the safety of the combination and differences in immune cell infiltrate in bone biopsies (bx) and preliminary clinical activit...
|
- Details
- In this Journal Club video presentation, Christopher Wallis, MD, PhD, and Zachary Klaassen, MD describe a Clinical Genitourinary Cancer publication Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. The primary objective of this analysis is to describe real-world treatment patterns, includ...
|
- Details
- Oliver Sartor, MD joins Alicia Morgans, MD, MPH to discuss a real-world clinical outcomes study of sequential novel antihormonal therapy (abiraterone or enzalutamide) or radium-223 (Ra-223) treatment of metastatic castration-resistant prostate cancer (mCRPC) that progressed after first-line NAH. This data is taken from the real world reports in the Flatiron Registry. Dr. Sartor presented this data...
|
- Details
- In conversation with Alicia Morgans, Philip Koo discusses data from a phase II trial that randomized patients to receive radium-223 and sipuleucel-T or sipuleucel-T alone. Dr. Koo explains that patients who received the combination saw a better PSA response, providing evidence for the continued exploration of the combination of radiation and immunotherapy. Biographies: Phillip J. Koo, MD , FACS Di...
|
- Details
- In this Journal Club, Zachary Klaassen and Christopher Wallis review the recently published New England Journal of Medicine article Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer, the double-blind, phase 3 PROSPER trial. Men with nonmetastatic, castration-resistant prostate cancer (defined on the basis of conventional imaging and a PSA doubling time of ≤10 months)...
|
- Details
- In an area where we have multiple options for treatment and we continue to have more data that helps to guide us, Evan Yu joins Alicia Morgans to speak about systemic treatment sequencing in the metastatic castration-resistant prostate cancer (mCRPC) setting and his approach to moving a patient through the different phases of their treatment. Biographies: Evan Yu, MD, Medical oncologist, treats pr...
|
- Details
- Matthew Smith shares his thoughts on the importance of bone health in the prostate cancer patient population. Osteoporotic or fragility fractures are common due to the age of the patient and long-term androgen deprivation therapy. Fractures have a great impact on patient mortality, mobility, independence, and overall quality of life. Dr. Smith addresses questions regarding bone density measurement...
|
